Magenta Therapeutics develops medicines for patients with blood cancers, genetic diseases, and autoimmune diseases using stem cell transplants. They have several drugs in clinical trials, including an anti-CD117 antibody and a CD45-antibody drug conjugate. They also have a cell therapy program for stem cell-based gene therapy and genome editing. Magenta has collaborations with AVROBIO and Beam Therapeutics. The company was founded in 2015 and is based in Cambridge, Massachusetts.